Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 2004

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

The contraceptive vaginal ring, NuvaRing, antimycotic co-medication.

AUTHORS

Verhoeven CH; van den Heuvel MW; Mulders TM; Dieben TO

SOURCE

Contraception. 2004 Feb;69(2):129-132.

ABSTRACT

We investigated the effect of antimycotic co-medication on the systemic exposure to etonogestrel (ENG) and

ethinylestradiol (EE) released from the contraceptive vaginal ring, NuvaRing. Different formulations of miconazole

nitrate and single as well as multiple dosing were investigated during two separate randomized, open-label,

crossover studies. The first study recruited 12 women to compare the effects of co-use of NuvaRing and a single

dose of antimycotic to NuvaRing alone. The second study recruited 14 women to compare the effects of multiple

doses of an antimycotic vaginal suppository to an antimycotic vaginal cream equivalent. Co-administration of all

three antimycotic formulations resulted in a slight increase in systemic exposure to ENG and EE over time, with

suppositories having a more pronounced effect than a cream formulation in the multiple-dosing study. The increases

in serum levels observed with the different antimycotic formulations are not expected to compromise NuvaRing's

contraceptive efficacy or tolerability. (PubHealth.info Document ID: CONT1T 516-06)

PubHealth.info NOTE: The author(s) of this article titled, "The contraceptive vaginal ring, NuvaRing, antimycotic co-

medication.", is(are) Verhoeven CH; van den Heuvel MW; Mulders TM; Dieben TO. The source of this article is

"Contraception. 2004 Feb;69(2):129-132.". This article was published in 2004 in English language(s).

(PubHealth.info® Document ID: CONT1T 516-06. All rights reserved with PubHealth.info) PIN: 516

This article is peer-reviewed.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.